Association of DNA methylation, polymorphism and mRNA level of ALAS1 with antituberculosis drug-induced liver injury

被引：0
|
作者：
Hao, Zhuolu [1 ]
Han, Bing [1 ]
Zhou, Xinyue [1 ]
Jian, Hongkai [2 ]
He, Xiaomin [3 ]
Lu, Lihuan [4 ]
Zhang, Meiling [5 ]
Pan, Hongqiu [6 ]
Yi, Honggang [1 ]
Tang, Shaowen [1 ]
机构：
[1] Nanjing Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Nanjing 211166, Peoples R China
[2] Nanjing Med Univ, Dept Internal Med, Clin Med Coll 1, Nanjing 211166, Peoples R China
[3] Peoples Hosp Taixing, Dept Infect Dis, Taixing 225400, Peoples R China
[4] Second Peoples Hosp Changshu, Dept TB, Changshu 215500, Peoples R China
[5] Jiangsu Univ, Jurong Hosp, Dept Infect Dis, Jurong 212400, Peoples R China
[6] Jiangsu Univ, Peoples Hosp Zhenjiang 3, Dept TB, Zhenjiang 212021, Peoples R China
来源：
PHARMACOGENOMICS | 2024年 / 25卷 / 10-11期
基金：
中国国家自然科学基金;
关键词：
ALAS1; AT-DILI; DNA methylation; SNP; synergistic effect; HEPATOTOXICITY; RIFAMPICIN;
D O I：
10.1080/14622416.2024.2392480
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Aim: To investigate the association of DNA methylation, genetic polymorphisms and mRNA level of aminolevulinate synthase 1 (ALAS1) with antituberculosis drug-induced liver injury (AT-DILI) risk. Methods: Based on a 1:1 matched case-control study with 182 cases and 182 controls, one CpG island and three single nucleotide polymorphisms (SNPs) were detected. ALAS1 mRNA level was detected in 34 samples. Results: Patients with methylation status were at high risk of AT-DILI (odds ratio: 1.567, 95% CI: 1.015-2.421, p = 0.043) and SNP rs352169 was associated with AT-DILI risk (GA vs. GG, odds ratio: 1.770, 95% CI: 1.101-2.847, p = 0.019). ALAS1 mRNA level in the cases was significantly lower than that in the controls (0.75 +/- 0.34 vs. 1.00 +/- 0.42, p = 0.021). Conclusion: The methylation status and SNP rs352169 of ALAS1 were associated with AT-DILI risk.
引用
收藏
页码：451 / 460
页数：10
相关论文
共 50 条
  • [41] Role of chemical structures and the 1331T>C bile salt export pump polymorphism in idiosyncratic drug-induced liver injury
    Ulzurrun, Eugenia
    Stephens, Camilla
    Crespo, Esperanza
    Ruiz-Cabello, Francisco
    Ruiz-Nunez, Julia
    Saenz-Lopez, Pablo
    Moreno-Herrera, Inmaculada
    Robles-Diaz, Mercedes
    Hallal, Hacibe
    Moreno-Planas, Jose M.
    Cabello, Maria R.
    Isabel Lucena, M.
    Andrade, Raul J.
    LIVER INTERNATIONAL, 2013, 33 (09) : 1378 - 1385
  • [42] AIBP protects drug-induced liver injury by inhibiting MAPK-mediated NR4A1 expression
    Ma, Tao
    Huang, Wei
    Ding, Yihong
    Ji, Ran
    Ge, Sijia
    Liu, Qingqing
    Liu, Yiheng
    Chen, Jing
    Yan, Yang
    Lu, Shushu
    Ren, Qiqi
    Fan, Yihui
    Mao, Renfang
    Lu, Cuihua
    ISCIENCE, 2024, 27 (10)
  • [43] Relationship of anti-tuberculosis drug-induced liver injury and genetic polymorphisms in CYP2E1 and GST
    Santos, Eliana Abreu
    Saraiva Goncalves, Jose Carlos
    Fleury, Marcos K.
    Kritski, Afranio L.
    Oliveira, Martha M.
    Velasque, Luciane S.
    Lapa e Silva, Jose Roberto
    Estrela, Rita de Cassia E.
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2019, 23 (06) : 381 - 387
  • [44] The hsa_circ_0082152 maintains NF-κB mRNA stability by binding to MTDH to promote anti-tuberculosis drug-induced liver injury
    Wang, Lin
    Meng, Chunyan
    Long, Yifei
    Liu, Yue
    Yang, Luming
    Gao, Xuelei
    Sun, Shufeng
    Feng, Fumin
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2024, 269
  • [45] DNA methylation may partly explain psychotropic drug-induced metabolic side effects: results from a prospective 1-month observational study
    Dubath, Celine
    Porcu, Eleonora
    Delacretaz, Aurelie
    Grosu, Claire
    Laaboub, Nermine
    Piras, Marianna
    von Gunten, Armin
    Conus, Philippe
    Plessen, Kerstin Jessica
    Kutalik, Zoltan
    Bin Eap, Chin
    CLINICAL EPIGENETICS, 2024, 16 (01)
  • [46] DNA methylation may partly explain psychotropic drug-induced metabolic side effects: results from a prospective 1-month observational study
    Céline Dubath
    Eleonora Porcu
    Aurélie Delacrétaz
    Claire Grosu
    Nermine Laaboub
    Marianna Piras
    Armin von Gunten
    Philippe Conus
    Kerstin Jessica Plessen
    Zoltán Kutalik
    Chin Bin Eap
    Clinical Epigenetics, 16
  • [47] CYP2S1 rs338599 polymorphism confers reduced risk to anti-tuberculosis drug-induced liver injury and may be a novel marker for its risk prediction
    Wang, Liyuan
    Wang, Hui
    Qi, Ying
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2022, 36 (06)
  • [48] Association of LEPR polymorphisms with predisposition and inflammatory response in anti-tuberculosis drug-induced liver injury: A pilot prospective investigation in Western Chinese Han population
    Zhao, Zhenzhen
    Peng, Wu
    Zhou, Juan
    Zhou, Yi
    Liu, Tangyuheng
    Bai, Hao
    Wu, Qian
    Song, Jiajia
    Wu, Lijuan
    Song, Xingbo
    Ying, Binwu
    INFECTION GENETICS AND EVOLUTION, 2019, 75
  • [49] Association between genetic polymorphisms of NRF2, KEAP1, MAFF, MAFK and anti-tuberculosis drug-induced liver injury: a nested case-control study
    Chen, Shixian
    Pan, Hongqiu
    Chen, Yongzhong
    Lu, Lihuan
    He, Xiaomin
    Chen, Hongbo
    Chen, Ru
    Zhan, Siyan
    Tang, Shaowen
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [50] Association of decreased mRNA expression of multidrug and toxin extrusion protein 1 in peripheral blood cells with the development of flutamide-induced liver injury
    Nakano, Kazuhiko
    Ando, Hitoshi
    Kurokawa, Shinsuke
    Hosohata, Keiko
    Ushijima, Kentarou
    Takada, Makoto
    Tateishi, Masato
    Yonezawa, Atsushi
    Masuda, Satohiro
    Matsubara, Kazuo
    Inui, Ken-ichi
    Morita, Tatsuo
    Fujimura, Akio
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (06) : 1191 - 1197
12345